Table 2.
Primary and subsequent treatment characteristics
| Positive study (n=7) | Negative study (n=21) | Overall (n=28) | |
|---|---|---|---|
| Primary treatment, n (%) | |||
| RP ± PLND | 6 (85.7) | 17 (81) | 23 (82.1) |
| RT ± ADT | 1 (14.3) | 4 (19) | 5 (17.9) |
| Subsequent treatment, n (%) | |||
| Local treatment*, n (%) | |||
| No | 3 (42.9) | 6 (28.6) | 9 (32.1) |
| Yes | 4 (57.1) | 15 (71.4) | 19 (67.9) |
| ADT, n (%) | |||
| Naïve | 2 (28.6) | 5 (23.8) | 7 (25) |
| First-line | 3 (42.9) | 15 (71.4) | 18 (64.3) |
| Second-line | 2 (28.6) | 1 (4.8) | 3 (10.7) |
| Chemotherapy, n (%) | |||
| Naïve | 6 (85.7) | 20 (95.2) | 26 (92.9) |
| Non-Naïve | 1 (14.3) | 1 (4.8) | 2 (7.1) |
RP, radical prostatectomy; PLND, pelvic lymph node dissection; RT, radiotherapy; ADT, androgen deprivation therapy.
*
Local treatment consisted of salvage RT (n=3 for positive and n=13 for negative subgroup) and cryoablation (n=1 for positive and n=2 for negative subgroup).